Does Pacific Edge have a target on its back?

Does Pacific Edge have a target on its back?
Invested capital in Cxbladder makes for an 'attractive acquisition target' (Image: supplied)
Brent Melville
Cancer diagnostic company Pacific Edge could be ripe for a takeover, analysis by investment firm Bell Potter suggests.Bell Potter, the Australian adviser to Pacific Edge’s September listing on the ASX, kicked off coverage of the Dunedin-based company with a speculative buy recommendation this week, valuing it at A$1.10 ($1.19) a share. That’s an 18% premium to Tuesday’s ASX price of 93 Australian cents, and a firm advance on its NZX Tuesday close of 99 cents. Local investment house Jarden pegs the NZX target price at $1.1...

More Markets

NZ sharemarket finishes flat, down 0.1%
Markets Market Close

NZ sharemarket finishes flat, down 0.1%

The S&P/NZX 50 Index closed at 13,480.43, down 19.42 points or 0.14%.

Sheep guts, big gains: Aroa’s 14% revenue lift
Markets

Sheep guts, big gains: Aroa’s 14% revenue lift

Soft tissue regeneration company remains debt-free.

Contact sets out aggressive growth push
Markets

Contact sets out aggressive growth push

Contact is relying on demand increase to fund expansion.